This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.

In this interview, Bertram Pitt, MD and Michelle L. O'Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.

post
Source

acc.org/latest-in-cardiology/articles/2021/10/04/11/00/accel-lite-2021oct06

Tags

Disease Condition ,Risk factors-comorbidities,Cardiovascular diabetes,Metabolic and Mixed disorders,Diabetes and Heart disorders,Renal Disease